Physician profile
Nathan S Box
NPI 1154520757
$799.79
in general payments reported to CMS, 2019-2025
23 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Facial Plastic Surgery provider received nationally (typical 2025 total: $271).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.39 · 2020: $31.52 · 2021: $80.32 · 2022: $236 · 2023: $130 · 2024: $147 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $411.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $146.62 | 2022-2024 | |
| Glaxosmithkline, LLC. | $116.53 | 2022-2023 | Nucala |
| Merck Sharp & Dohme LLC | $48.09 | 2023-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Convatec INC. | $44.06 | 2024 | |
| Kls-Martin L.P. | $40.39 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $39.47 | 2023 | Dupixent |
| Sanofi-Aventis U.S. LLC | $36.54 | 2021 | |
| Genentech USA, INC. | $33.40 | 2021-2025 | Xolair |
| Lilly USA, LLC | $32.54 | 2025 | Kisunla, Mounjaro |
| Alk-Abello, INC | $29.08 | 2020-2022 | |
| United Therapeutics Corporation | $25.26 | 2025 | Tyvaso |
| Novartis Pharmaceuticals Corporation | $24.58 | 2023 | |
| Medtronic, INC. | $24.57 | 2022 | |
| Averitas Pharma INC. | $24.20 | 2023 | Qutenza |
| Stryker Corporation | $20.49 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $18.00 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $15.35 | 2025 | |
| Mimedx Group, INC. | $15.34 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.04 | 2024 | Gattex |
| Kerecis Limited | $14.97 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Abbvie INC. | $14.46 | 2024 | |
| Optinose US, INC. | $11.39 | 2021 | |
| Phathom Pharmaceuticals, INC. | $9.42 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Box listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.